Odanacatib

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.

It is being developed by Merck & Co., Merck is conducting phase III clinical trials.